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Abstract
The risk of venous thromboembolism in oral contraceptive pill users becomes dramatically increased in
patients with inherited thrombophilias. The often undiscovered prothrombotic genetic conditions pose a
potentially deadly threat to its generally young demographic. When thrombosis is discovered in oral
contraceptive pill users with a strong family history of related events, it becomes essential to screen for
prothrombotic genetic conditions and further mitigate any associated modifiable risk factors. Here we
present a case of pulmonary embolism requiring cardiopulmonary resuscitation in 30-year-old female
found to have a Prothrombin G20210A on oral contraceptive pills. The emergent management of the
critical case, as well as the subsequent evaluation for prothrombotic conditions and the role of potential
screening is discussed.
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Abstract
The risk of venous thromboembolism in oral contraceptive pill users becomes dramatically increased in patients with
inherited thrombophilias. The often undiscovered prothrombotic genetic conditions pose a potentially deadly threat to
its generally young demographic. When thrombosis is discovered in oral contraceptive pill users with a strong family
history of related events, it becomes essential to screen for prothrombotic genetic conditions and further mitigate any
associated modiﬁable risk factors. Here we present a case of pulmonary embolism requiring cardiopulmonary resuscitation in 30-year-old female found to have a Prothrombin G20210A on oral contraceptive pills. The emergent management of the critical case, as well as the subsequent evaluation for prothrombotic conditions and the role of potential
screening is discussed.
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1. Introduction

T

he three essential factors in the development
of venous thrombosis are characterized by
Virchow's triad-hypercoagulability, venous stasis,
and venous damage. Risk factors for hypercoagulability include obesity, smoking, surgery, immobility,
the use of oral contraceptive pills (OCPs), pregnancy
and a personal or family history of inherited
thrombophilias such as Factor V Leiden, Prothrombin G20210A, deﬁciencies of protein C, protein S, or antithrombin. Oral contraceptive pill
(OCP) use is associated with an increased risk of
venous thromboembolism (VTE), the incidence of
which is exponentially pronounced in women with
hereditary thrombophilias.1 The Prothrombin
G20210A mutation, present in anywhere from 0.7 to
8.0% of the healthy population, is a single missense
mutation at the 20210 nucleotide position which
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contraceptives,

Venous

results in a 133% increase in blood levels prothrombin.2 This case describes a young woman
presenting with an unprovoked pulmonary embolism with workup for potential etiology revealing an
inherited thrombophilia disorder, as well as OCP
use as an additional contributing factor. The purpose of this report is to emphasize the importance of
hypercoagulability workup when presented with an
unprovoked thromboembolism and prevention
strategies in patients with family history or current
diagnosis of inherited thrombophilias.

2. Case presentation
A 30-year-old female with no signiﬁcant past
medical or surgical history, presented with two
weeks of progressive shortness of breath. The only
medication she took prior to admission were combined estrogen and progestin OCPs, started shortly
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after the natural birth of her daughter three years
ago. She notably did have a known family history of
multiple miscarriages in her mother and a cousin
with a thrombotic stroke at the age of 23, with a
normal BMI of 24.1 (weight 59.4 kg, height 157 cm),
was a non-smoker, and did not recently have any
trauma, surgery, or prolonged immobility of any
kind. Upon arrival to the Emergency Department,
her symptoms progressed rapidly, as the patient
lost consciousness within 5 min and developed
cardiac arrest due to severe right heart strain,
necessitating cardiopulmonary resuscitation. Due to
the rapid progression of her course, her ﬁrst
recorded vitals were post-intubation with a temperature of 36  C, heart rate of 80, respiratory rate of
20, blood pressure of 111/51 mmHg, and pulse oxygen of 100% on 60% FiO2. A CT pulmonary
angiogram revealed pulmonary emboli causing
complete occlusion of the lower lobe pulmonary
arteries bilaterally (Fig. 1). Tissue plasminogen
activator (tPA) was emergently administered followed by thrombectomy and thrombolysis of the
pulmonary emboli (Fig. 2). After the patient was
stabilized, investigation for hypercoagulable medical disorders revealed an underlying Prothrombin
G20210A gene mutation, also known as Factor II
mutation. Patient was negative for Factor V Leiden
gene mutations, PTG gene mutations, and Cardiolipin antibodies.
Findings from the investigation suggest that the
combination of an inherited thrombophilia disorder as well as OCP use was likely the contributing
factors in her development of unprovoked VTE in
the form of a pulmonary embolus, as patient
lacked other risk factors or etiologies for her
condition.

3. Discussion
While the risk of thrombosis with OCP is well
researched and established, it must further be
emphasized that OCP users who are also carriers of
prothrombin gene mutation G20210A have a 16-fold
increased risk of VTE in comparison to non-OCP users
without prothrombotic genetic mutations.3 It stands to
reason that any possible triggers of this often-quiescent disease must be avoided, demonstrating the
importance of a hypercoagulability workup when
presented with a VTE in an otherwise healthy young
female, as seen in our case. Current WHO recommendations advise against the use of hormone based
OCPs in women with inherited thrombophilias as
they pose an unacceptable health risk.4 Primary prevention by identifying these disorders with targeted
questions prior to initiating OCPs, including inquiry
into personal and family history of stroke and pulmonary embolism, in conjunction with a thorough
history, can be lifesaving and avoid unanticipated
VTEs. Recognition of known extrinsic risk factors such
as OCP use and smoking history should also be performed. Screening for common genetic mutations
seen in inherited thrombophilias such as Prothrombin
gene mutations, Factor V Leiden and Antithrombin
mutations should be done if suspicion is high based on
history intake. However, the WHO advises against
routine screening for thrombophilia prior to initiating
OCPs due to high screening cost as well as low prevalence of the disorders, so appropriate assessment of
personal and family history is vital.5 In those with
prothrombic genetic conditions, the need for long
term anticoagulation should be assessed. Secondary
prevention by educating patients using OCPs should
be encouraged, especially if patient has a known
prothrombotic genetic mutation. It becomes

Fig. 1. CTA Chest in multiple planes demonstrating bilateral pulmonary embolisms. Sagittal image of the right lung with a ﬁlling defect in the right
middle lobe branch (a). A coronal image of the chest with bilateral pulmonary emboli involving the left main pulmonary artery and the right anterior
segmental artery (b). Sagittal image of the left lung with a ﬁlling defect in the left main pulmonary artery (c).

https://scholar.rochesterregional.org/advances/vol2/iss2/10
DOI: 10.53785/2769-2779.1097

2

Darwish et al.: Risk of Thromboembolism with Prothrombin-G20210A Mutation and OCPs

Fig. 2. Digital subtraction angiography of right and left lungs. A single coronal DSA frame of the right lung with near total opaciﬁcation of the right
pulmonary segmental branches (a). DSA coronal image of the left pulmonary artery with incomplete opaciﬁcation of the basilar segments (b). Single
coronal DSA image following catheter directed thrombolysis demonstrating complete opaciﬁcation of the left basilar segmental arteries is appreciated (c).

paramount for physicians to counsel such patients to
avoid additional risk factors that could contribute to
the development of a VTE, such as obesity, smoking,
hormone replacement therapy, and prolonged
immobility.
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